Algert Global LLC Lowers Position in ICU Medical, Inc. (NASDAQ:ICUI)

Algert Global LLC lowered its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 77.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,450 shares of the medical instruments supplier's stock after selling 19,239 shares during the quarter. Algert Global LLC's holdings in ICU Medical were worth $993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in ICUI. Russell Investments Group Ltd. increased its position in ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier's stock valued at $59,000 after acquiring an additional 173 shares during the period. Jane Street Group LLC increased its holdings in ICU Medical by 79.7% in the first quarter. Jane Street Group LLC now owns 89,852 shares of the medical instruments supplier's stock valued at $9,643,000 after purchasing an additional 39,839 shares during the period. Virtu Financial LLC bought a new position in ICU Medical during the 1st quarter worth $288,000. Boston Partners bought a new position in ICU Medical during the 1st quarter worth $790,000. Finally, Moody National Bank Trust Division lifted its holdings in ICU Medical by 9.0% during the 2nd quarter. Moody National Bank Trust Division now owns 12,828 shares of the medical instruments supplier's stock worth $1,523,000 after buying an additional 1,054 shares during the period. Institutional investors own 96.10% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Raymond James increased their price target on ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a research note on Thursday, September 12th. StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, November 20th. KeyCorp boosted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 13th. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research report on Wednesday, November 13th. Finally, Jefferies Financial Group assumed coverage on shares of ICU Medical in a research note on Monday, October 14th. They set a "hold" rating and a $183.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $173.00.

ICU Medical Stock Up 2.6 %

NASDAQ ICUI traded up $4.21 on Friday, hitting $163.96. 159,148 shares of the company were exchanged, compared to its average volume of 274,156. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a market cap of $4.01 billion, a PE ratio of -35.88 and a beta of 0.66. The stock has a fifty day moving average of $174.60 and a 200-day moving average of $147.08. ICU Medical, Inc. has a 12 month low of $83.26 and a 12 month high of $196.26.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the firm's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company's stock, valued at approximately $18,665,666.78. This trade represents a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Greenberg sold 972 shares of ICU Medical stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total transaction of $153,682.92. Following the transaction, the director now owns 5,037 shares of the company's stock, valued at $796,400.07. This represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,364 shares of company stock valued at $6,876,478 in the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.